RUB 16 Million Will be Spent on a Clinical Trial for a Russian Coronavirus Vaccine

18 June 2020

GMP News

The Gamaleya Research Center for Epidemiology and Microbiology of the Ministry of Health of the Russian Federation will spend almost 16 million rubles to study a vaccine for the new coronavirus, and then test it on 60 volunteers.

According to the published data, the contractor will carry out the research work (R&D). The contract is valid from the moment the contract is signed until November 30th, 2020. However, there is a caveat that the work must be completed as soon as possible.

Under the terms of the contract, the performer is obliged to conclude insurance contracts for volunteers, prepare all necessary documentation for the study, purchase consumables, conduct clinical trials, and prepare a report for the Russian Ministry of Health on the results of the studies.

The study will be conducted in two stages, each with an equal number of volunteers of both sexes aged 18-60 years inclusive, a total of 60 people. Volunteers will be recruited from a group of 100 people previously surveyed. Participants will be monitored within 28 days of the vaccine being administered. After discharge from hospital, there will be another check-up on day 42.

Source
Print

Shareholders

Read more

Pipeline

Read more

Media Center

Read more